GLP-1 and GIP receptor agonism reducing energy intake.
What was measuredPhase 2 (n≈338): mean weight loss ≈24.2% at 48 weeks on the highest dose. Phase 3 is under way and has not reported.
Also known as LY3437943 · triple agonist · developed by Eli Lilly
Large randomised trials in humans are complete or under way, but the compound is not licensed. Efficacy and common adverse effects are reasonably well characterised; long-term safety may not be.
An investigational agonist at three receptors — GIP, GLP-1 and glucagon. The glucagon component is what distinguishes it, and is intended to raise energy expenditure alongside the appetite suppression the other two provide.
Triple agonist. Glucagon receptor activation increases hepatic energy expenditure and lipolysis, which in principle adds a metabolic-rate effect to the intake reduction seen with GLP-1 and GIP agonism.
A phase 2 trial published in the New England Journal of Medicine in 2023 reported mean weight loss of approximately 24% at 48 weeks at the highest dose, in 338 participants. Weight had not clearly plateaued when the trial ended.
The TRIUMPH programme is running across obesity, type 2 diabetes, knee osteoarthritis and cardiovascular outcomes. Results are not yet available.
This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.
Not approved by any regulator anywhere in the world. It is an investigational product, legally available only through the clinical trials running it.
The sites below are where Retatrutide is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.
Drag to turn · tap an organ
GLP-1 and GIP receptor agonism reducing energy intake.
What was measuredPhase 2 (n≈338): mean weight loss ≈24.2% at 48 weeks on the highest dose. Phase 3 is under way and has not reported.
Increases glucose-dependent insulin secretion and suppresses glucagon.
What was measuredPhase 2 glycaemic endpoints were favourable. No phase 3 outcome data exists yet.
Glucagon receptor agonism is proposed to raise hepatic energy expenditure and lipolysis.
What was measuredThis is the arm that distinguishes it from dual agonists. The size of its contribution in humans is not yet established.
A long-acting analogue of GLP-1, a hormone the gut releases after eating. Structural changes — an Aib substitution that …
A single molecule that activates two incretin receptors — GIP and GLP-1 — built on a GIP backbone with substitutions tha…
A fragment of the C-terminus of human growth hormone, developed specifically as a weight-loss drug on the theory that th…
This site publishes summaries of published research. It is not medical advice, and Genexis Health does not sell or supply any compound described here. Please confirm each statement below to continue.
We ask everyone to confirm they understand this site is information rather than medical advice before reading it. Because you have not confirmed those statements, you cannot continue.
If you are looking for health advice or treatment, please speak to a licensed healthcare professional. Nothing on this site is a substitute for that.